Frontiers in pharmacology · 2026
A novel pyrrolidine-chalcone derivative exhibits synergistic anti-cervical cancer activity by dual-targeting MDM2-p53 axis and ferroptosis pathway.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xiamuxi Hainimu, Deng XinYi, Ablise Mourboul, Yan Tong, Imam Madina, Wang Yu, Zu MingHui, Wumaier Wutiekuer
Аннотация
INTRODUCTION: Cervical cancer remains a serious threat to women's health, driving the need for effective and low-toxicity therapeutics. This study designed novel pyrrolidine-chalcone derivatives targeting the MDM2-p53 interaction.
METHODS: A series of compounds were synthesized and evaluated for cytotoxicity against cervical cancer (HeLa, SiHa, C33A) and normal (H8) cells via CCK-8. The lead compound B1 was further analyzed for p53 pathway activation, apoptosis, and ferroptosis markers (ROS, GSH, MDA, Fe2+) using western blot, flow cytometry, and assay kits.
RESULTS: Compound B1 showed potent, nanomolar cytotoxicity (IC50 = 0.22, 0.24, and 0.95 μM for HeLa, SiHa, and C33A, respectively) with low toxicity to H8 cells. B1 activated p53 by downregulating MDM2, inducing cell cycle arrest and apoptosis. Simultaneously, it triggered ferroptosis via ROS accumulation, GSH depletion, elevated MDA and Fe2+, and suppression of SLC7A11/GPX4.
DISCUSSION: B1 is a promising dual-mechanism lead compound against cervical cancer, concurrently activating p53 and ferroptosis, warranting further investigation.
METHODS: A series of compounds were synthesized and evaluated for cytotoxicity against cervical cancer (HeLa, SiHa, C33A) and normal (H8) cells via CCK-8. The lead compound B1 was further analyzed for p53 pathway activation, apoptosis, and ferroptosis markers (ROS, GSH, MDA, Fe2+) using western blot, flow cytometry, and assay kits.
RESULTS: Compound B1 showed potent, nanomolar cytotoxicity (IC50 = 0.22, 0.24, and 0.95 μM for HeLa, SiHa, and C33A, respectively) with low toxicity to H8 cells. B1 activated p53 by downregulating MDM2, inducing cell cycle arrest and apoptosis. Simultaneously, it triggered ferroptosis via ROS accumulation, GSH depletion, elevated MDA and Fe2+, and suppression of SLC7A11/GPX4.
DISCUSSION: B1 is a promising dual-mechanism lead compound against cervical cancer, concurrently activating p53 and ferroptosis, warranting further investigation.